Table 1.

Demographic characteristics, CSF AD core biomarkers and synaptic biomarkers concentration for the discovery and the validation cohorts

	Discovery cohort		Clinical cohort from Paris
Patient group	Non-AD (n=19)	AD (n=21)	NC (n=22)	MCI-AD (n=44)	AD dementia (n=77)	Non-AD MCI (n=46)	Non-AD Dementia (n=28)
Sex (male/female)	7/11¤	12/9	8/14	17/27	28/49	17/29	16/12
Age (years) mean, [SD]	54.2 [8.7]	72.4 [9.7]	64.4 [8.86]	72 [7.7]*&	72.2 [8.33]*&	67 [10]#	66 [7.5]#
MMSE, mean, [SD]	-	-	27.14 [2.34]	23.34[4.54]⁎#	19.06 [5.63]*	24.5 [3.65]#	23.5 [4.95]#
Biomarkers
Aβ42 [pg/ml] mean, [SD]	891 [173.32]	346.9 [86.26]	1095.9 [277.09]	599 [332.04]*&	508.33 [160.9]*&	1080.5 [419.8]#	974.9 [380.9]#
Aβ42/Aβ40 mean, [SD]	-	-	0.093 [0.009]	0.046 [0.012]*&	0.042 [0.009]*&	0.090 [0.010]#	0.089 [0.014]#
t-Tau [pg/ml] mean, [SD]	227.6 [65.56]	530.19 [46.60]	243.09 [66.09]	594.63 [268.8]*&	731.79 [384.9]*&	296.35 [139.6]#	329.1 [303.7]#
p-Tau [pg/ml] mean, [SD]	37.28 [8.95]	67.43 [3.89]	32.84 [8.06]	92.42 [46.06]*#&	112.59 [55.86]*&	37.07 [15.41]#	34 [10.63]#
Neurogranin [pg/ml] mean, [SD]	-	-	131.69 [40.19]	259.8 [82.72]*&	268.72 [78.61]*&	172.4 [45.11]#	163.3 [49.47]#
GAP43 [pg/ml] mean, [SD]	-	-	2427.26 [707.16]	4071.3 [1889.2]*&	4497 [1828.5]*	3071.58 [1263.7]#	3012.9 [1422.6]#

Abbreviations: AD= Alzheimer's disease, NC=neurological controls, MCI=mild cognitive impairment, GAP43=growth-associated protein 43, MMSE=Mini-Mental State Examination, SD=standard deviation

^¤One missing data

Notes: Analysis of variance followed by Tukey's post hoc test (continuous variables) or contingency chi-square test (sex), were used to test differences between the groups. Significant differences compared to control (*) or AD (#) or non-AD dementia (&) in the same cohort are highlighted. Significance level set to p ≤ 0.05.

I will add the difference between the groups in the Paris cohort